Drug-eluting technologies in femoral artery lesions

Departement Vascular Surgery , A.Z. Sint‑Blasius, Dendermonde, Belgium - .
The Journal of cardiovascular surgery (Impact Factor: 1.46). 04/2013; 54(2):217-24.
Source: PubMed


The treatment of femoropopliteal lesions has known an important evolution in the last years. An important limitation of current endovascular therapy remains the occurrence of restenosis. In order to minimize restenosis rates, drug eluting technologies are evolving. The use of drug-eluting stents (DES) in coronary arteries shows beneficial results, leading to investigation of DES in femoropopliteal arteries. In this article, we give an overview of current available data on treatment with drug eluting technologies in the superficial femoral artery (SFA). This paper su mmarizes also the current available data of the use of drug-coated balloons (DCB) in the femoropopliteal tract. Currently, no data are available on the use of DCB in long lesions. A drug eluting bioresorbable scaffold seems to be very promising in coronary arteries. The transfer to the peripheral area is nowadays ongoing. Which technique and device for which lesion and patient requires further investigation to build up a real evidence based SFA treatment strategy.

9 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trotz initial guter Erfolge nach Angioplastie bei peripherer arterieller Verschlusskrankheit (pAVK) bilden Restenosen das Hauptproblem. Sie werden durch neointimale Hyperplasie verursacht und können mithilfe antiproliferativer Substanzen effektiv unterdrückt werden. Zur längerfristigen Hemmung werden medikamentenbeschichtete Ballonkatheter (,,drug-coated balloon“, DCB) und -“drug-coated stents“ (DCS) eingesetzt.Die vorliegende Arbeit gibt einen Überblick über die DCB-Entwicklung, die aktuell eingesetzten Systeme und die vorliegenden klinischen Studien. Die Evidenz in der Behandlung der femoropoplitealen Arterien wird diskutiert.Es wurde eine systematische elektronische Literaturrecherche in Datenbanken medizinischer Fachzeitschriften, international registrierter klinischer Studien und publizierter Kongressbeiträge zum DCB-Einsatz im infrainguinalen Bereich im Zeitraum 2008 bis Juli 2013 durchgeführt.Hauptvorteile der DCB sind, dass kein Metall im Gefäß zurückbleibt, die unmittelbare Freisetzung hoher Substanzkonzentrationen und ihre Einsetzbarkeit in Bereichen, in denen DCS bisher kontraindiziert sind. Die klinische Evidenz der ,,paclitaxel drug-coated balloon“ (PTX-DCB) der 1. Generation wurde in verschiedenen kontrollierten randomisierten Studien aufgezeigt.In Abhängigkeit von der Läsionsart und dem Läsionsort sind DCB geeignet bei In-Stent-Restenosen, Restenosen oder in Bereichen der A. poplitea oder bei Seitenästen der A. profunda, in denen eine Stent-Applikation kontraindiziert ist.
    Gefässchirurgie 10/2013; 18(6). DOI:10.1007/s00772-013-1226-5 · 0.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyvinylpyrrolidone (PVP) is a conventionally applied hydrophilic lubricious coating on catheter-based cardiovascular devices, used in order to ease movement through the vasculature. Its use as drug reservoir and transfer agent on drug-coated balloons (DCB) is therefore extremely promising with regard to the simplification of its approval as a medical device. Here, we developed a PVP-based coating for DCB, containing paclitaxel (PTX) as a model drug, and studied the impact of crosslinking via UV radiation on drug stability, wash off, and transfer during simulated use in an in vitro vessel model. We showed that crosslinking was essential for coating stability and needed to be performed prior to PTX incorporation due to decreased drug bioavailability as a result of photodecomposition and/or involvement in vinylic polymerization with PVP under UV radiation. Moreover, the crosslinking time needed to be carefully controlled. While short radiation times did not provide enough coating stability, associated with high wash off rates during DCB insertion, long radiation times lowered drug transfer efficiency upon balloon expansion. A ten minutes radiation of PVP, however, combined a minimized drug wash off rate of 34% with an efficient drug transfer of 49%, underlining the high potential of photochemically crosslinked PVP as a coating matrix for DCB.
    Coatings Magazine 12/2013; 3(3):253-267. DOI:10.3390/coatings3040253
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endovascular treatment has become first--line approach for revascularization of long and complex femoropopliteal lesions in many centers. This development urges the need for endovascular approaches with a sustainable success in terms of patency. In several recently published trials the VIABAHN endoprosthesis has shown promising patency rates comparable or even better than traditional surgical bypass procedures with prosthetic material.
    The Journal of cardiovascular surgery 06/2014; 55(4). · 1.46 Impact Factor
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.